Literature DB >> 9510558

Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient.

H Kobayashi1, T Kokubo, M Takahashi, K Sato, N Miyokawa, S Kimura, R Kinouchi, M Katagiri.   

Abstract

Human T-cell-mediated autoimmune diseases are often genetically linked to particular alleles of HLA class II genes. Vogt-Koyanagi-Harada's (VKH) disease, which is regarded as an autoimmune disorder in multiple organs containing melanocytes, has been found to be associated with HLA-DR4 (DRB1(*)0405) and HLA-DR53 (DRB4(*)0101). Tyrosinase is a melanoma antigen (Ag) expressed by normal melanocytes as well as melanoma cells against which responses by autologous T cells have been detected. We established a T-cell line from the peripheral blood of a patient with VKH disease which responded to synthetic peptides corresponding to tyrosinase. The T-cell line was generated which recognized the tyrosinase p188 - 208 peptide when presented by the HLA-DR4 (DRB1(*)0405) molecule on the surface of HLA class II-expressing L-cell transfectants. The minimal antigenic peptide which induced T-cell responses was an 11-amino-acid sequence and located at tyrosinase p193 - 203 (E-I-W-R-D-I-D-F-A-H-E). This peptide contained the DRB1(*)0405-binding peptide motif (hydrophobic residues (Y, F, W) at position 1 as an anchor residue, and negatively charged residues (D, E) at position 9), which corresponded to the W at p195 and the D at p203. These observations demonstrate that tyrosinase peptides are immunogenic, and may be a candidate for an autoantigen in VKH disease, suggesting that probing the T-cell responses against synthetic peptides is a productive approach for identifying the autoantigenic peptides associated with autoimmune diseases including VKH disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9510558     DOI: 10.1007/s002510050375

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  9 in total

Review 1.  CD4 T cells in tumor immunity.

Authors:  Mara Gerloni; Maurizio Zanetti
Journal:  Springer Semin Immunopathol       Date:  2005-03-15

Review 2.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

Review 3.  Immune targets and neoantigens for cancer immunotherapy and precision medicine.

Authors:  Rong-Fu Wang; Helen Y Wang
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

4.  Outcomes of patients with acute Vogt-Koyanagi-Harada disease treated with intravenous corticosteroid pulse followed by the slow tapering of oral corticosteroid therapy.

Authors:  Rui Fushitsu; Akihiro Ishibazawa; Masataka Murono; Reiko Kinouchi
Journal:  Int Ophthalmol       Date:  2022-07-22       Impact factor: 2.029

5.  Frequent immune response to a melanocyte specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease.

Authors:  S Otani; T Sakurai; K Yamamoto; T Fujita; Y Matsuzaki; Y Goto; Y Ando; S Suzuki; M Usui; M Takeuchi; Y Kawakami
Journal:  Br J Ophthalmol       Date:  2006-02-15       Impact factor: 4.638

6.  Prognostic factors in Vogt-Koyanagi-Harada disease.

Authors:  Abdullah S Al-Kharashi; Hassan Aldibhi; Hamad Al-Fraykh; Dustan Kangave; Ahmed M Abu El-Asrar
Journal:  Int Ophthalmol       Date:  2007-04-14       Impact factor: 2.029

Review 7.  miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease.

Authors:  Fabian Vega-Tapia; Mario Bustamante; Rodrigo A Valenzuela; Cristhian A Urzua; Loreto Cuitino
Journal:  Front Cell Dev Biol       Date:  2021-05-10

8.  Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan.

Authors:  Carl P Herbort; Manabu Mochizuki
Journal:  Int Ophthalmol       Date:  2007-04-28       Impact factor: 2.029

9.  Pseudotumoral and Multiple Retinal Pigment Epithelium Proliferation in Vogt-Koyanagi-Harada Disease.

Authors:  Juan B Yepez; Felipe Murati; Michele Petitto; J Fernando Arevalo
Journal:  Case Rep Ophthalmol Med       Date:  2015-10-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.